COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：3
|
作者：
Zhang, X. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ So Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.351
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND20
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [41] Early versus delayed initiation of fingolimod or dimethyl fumarate in relapsing-remitting multiple sclerosis
    Lorscheider, J.
    Schadelin, S.
    Benkert, P.
    Lienert, C.
    Hanni, P.
    Derfuss, T.
    Decard, B.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 257 - 258
  • [42] Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
    Fisher, E.
    Nakamura, K.
    Lee, J-C
    You, X.
    Sperling, B.
    Rudick, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (05) : 668 - 676
  • [43] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
  • [44] COST-MINIMIZATION ANALYSIS OF TERIFLUNOMIDE AND DIMETHYL FUMARATE FOR TREATMENT OF RELAPSING-REMITTING FORMS OF MULTIPLE SCLEROSIS IN ITALY
    Stanisic, S.
    Bergamaschi, R.
    Berto, P.
    Di Procolo, P.
    Marocco, A.
    Morawski, J.
    VALUE IN HEALTH, 2018, 21 : S341 - S341
  • [45] Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis
    Centonze, Diego
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Giuliani, Luigi
    Canonico, Pier Luigi
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2018, 19 (01) : 47 - 52
  • [46] Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Terzi, Murat
    Ozer, Bilge
    Turkoglu, Recai
    Karabudak, Rana
    Efendi, Husnu
    Soysal, Aysun
    Sevim, Serhan
    Altintas, Ayse
    Kurne, Asli
    Akcali, Aylin
    Akman, Gulsen
    Yuceyar, Nur
    Balci, Belgin Petek
    Ekmekci, Ozgul
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Altunrende, Burcu
    Turan, Omer Faruk
    GozubatikCelik, Gokcen
    Kale, Nilufer
    Koseoglu, Mesrure
    Ozakbas, Serkan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 36
  • [47] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON BETA-1A IN ITALIAN RELAPSING REMITTING MULTIPLE SCLEROSIS MANAGEMENT
    Iannazzo, S.
    Santoni, L.
    Saleri, C.
    Puma, E.
    Vestri, G.
    Giuliani, L.
    Canonico, P. L.
    Centonze, D.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [48] Cost-effectiveness analysis of peginterferon beta-1a in Italian relapsing remitting multiple sclerosis management
    Iannazzo, Sergio
    Santoni, Laura
    Saleri, Cecilia
    Puma, Elisa
    Vestri, Giulia
    Giuliani, Luigi
    Canonico, Pier Luigi
    Centonze, Diego
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 : 13 - 36
  • [49] COST-EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON BETA-1A IN PORTUGAL BASED ON THE FINDINGS OF COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Silverio, N.
    Sequeira, L.
    Meletiche, D.
    VALUE IN HEALTH, 2014, 17 (07) : A398 - A398
  • [50] Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
    Nehzat, Nasim
    Mirmosayyeb, Omid
    Barzegar, Mahdi
    Vosoughi, Reza
    Fazeli, Erfane
    Shaygannejad, Vahid
    NEUROLOGY RESEARCH INTERNATIONAL, 2021, 2021
12345